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The excess of growth hormone secretion,
hypersomatotropism, may induce the acromegalic
syndrome. It is caused by the anabolic effects of IGF-1
synthesized in the liver.
Hypersomatotropism is underdiagnosed and might be the
cause of >30% of insulin resistant feline diabetes mellitus.
✓ Establish the acromegaly prevalence based
on retrospective studies and clinical trials.
✓ Review diagnostic update.
✓ Update treatment alternatives.
ObjectivesIntroduction
Feline acromegaly may be caused by either
adenohypophyseal adenoma or hyperplasia of acidophilic
cells.
There are genetic and environmental predisposing factors
that induce the AIP gen mutation.
There is higher incidence in european short- hair, middle-
aged/older male neutered cats.
Etiology
CLINICAL SIGNS AND PHYSICAL EXAMINATION 
FINDINGS IN CATS WITH ACROMEGALY*
CLINICAL FINDINGS PERCENT OF 
OCCURRENCE
Diabetes mellitus (usually
poorly controlled)
96 – 100%
PU/PD 83 – 100%
Polyphagia 78 – 100%
Enlargment of head,
abdomen and paws
50 – 83%
Prognathia inferior 35 – 71%
Wight gain 35 – 59%
Hepatomegaly and/or
renomegaly
26 – 100%
Heart murmur and/or gallop
rhythm
17 – 64%
Wight loss 9 – 57%
CNS signs 9 – 14%
Diabetic neuropathy 6 – 26%
Enlargement of the tongue 6 – 21%
Lameness or degenerative
arthropathy
5 – 43%
Respiratory stridor 4 – 53%
Blood test Imaging 
Serum biochemical analysis 
and urianalysis 
Echography 
Serum total IGF – 1 
concentrations (false 
positives and negatives) 
Echocardiography 
Serum GH concentrations CT 
Serum ghrelin 
concentrations 
MRI 
Serum PIIIP (type III 
procollagen propeptide) 
concentration 
 
Diagnostic tools
Feline acromegaly is underdiagnosed: ≥30%
of insulin resistant diabetic cats may be
acromegalic.
• The environmental factors could be a cause of
the increase of the syndrome
• Underdiagnose is due to the variability of clinical
signs and the imperfection diagnostic tools
There are many ineffective or inaccessible
treatments, but long-acting pasireotide could
offer a good pharmacological solution.
Conclusions
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